Literature DB >> 16772158

Pregnancy complications in PCOS.

Roy Homburg1.   

Abstract

Complications of pregnancy associated with maternal PCOS include increased prevalence of early pregnancy loss (EPL), gestational diabetes (GDM), pregnancy-induced hypertensive disorders (PET/PIH), and the birth of small-for-gestational-age (SGA) babies. Increased risk of EPL has been attributed to obesity, hyperinsulinaemia, elevated luteinizing hormone concentrations, and endometrial dysfunction. Avoiding obesity before pregnancy and treatment with metformin are therapeutic options, also for the increased prevalence of GDM. Administration of metformin throughout pregnancy is a contentious issue. Screening pregnant women with PCOS for GDM and PET/PIH-especially if they are obese-is recommended, although data for a firm association between PCOS and PET/PIH is weak. Impaired insulin-mediated growth and fetal programming are possible explanations for a higher prevalence of SGA infants in mothers with PCOS. Only prospective studies employing a large cohort of women with well-defined PCOS compared with a control group matched for BMI and parity can solve the remaining questions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16772158     DOI: 10.1016/j.beem.2006.03.009

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  24 in total

1.  Exposing cultured mouse ovarian follicles under increased gonadotropin tonus to aromatizable androgens influences the steroid balance and reduces oocyte meiotic capacity.

Authors:  Sergio Romero; Johan Smitz
Journal:  Endocrine       Date:  2010-07-20       Impact factor: 3.633

Review 2.  Diagnostic criteria for polycystic ovarian syndrome.

Authors:  F J Broekmans; B C J M Fauser
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

Review 3.  Polycystic ovary syndrome.

Authors:  Zi-Jiang Chen; Yuhua Shi
Journal:  Front Med China       Date:  2010-08-12

4.  The effect of insulin signaling on female reproductive function independent of adiposity and hyperglycemia.

Authors:  Anindita Nandi; Xiangyuan Wang; Domenico Accili; Debra J Wolgemuth
Journal:  Endocrinology       Date:  2010-02-22       Impact factor: 4.736

5.  Spindle and chromosome configurations of in vitro-matured oocytes from polycystic ovary syndrome and ovulatory infertile women: a pilot study.

Authors:  Rodolpho C Vieira; Ionara D Barcelos; Elisa M Ferreira; Wellington P Martins; Rui A Ferriani; Paula A Navarro
Journal:  J Assist Reprod Genet       Date:  2010-09-04       Impact factor: 3.412

6.  Developmental Programming: Prenatal and Postnatal Androgen Antagonist and Insulin Sensitizer Interventions Prevent Advancement of Puberty and Improve LH Surge Dynamics in Prenatal Testosterone-Treated Sheep.

Authors:  Vasantha Padmanabhan; Almudena Veiga-Lopez; Carol Herkimer; Bachir Abi Salloum; Jacob Moeller; Evan Beckett; Rohit Sreedharan
Journal:  Endocrinology       Date:  2015-04-28       Impact factor: 4.736

7.  Changes in the expression of insulin signaling pathway molecules in endometria from polycystic ovary syndrome women with or without hyperinsulinemia.

Authors:  Romina Fornes; Paulina Ormazabal; Carlos Rosas; Fernando Gabler; David Vantman; Carmen Romero; Margarita Vega
Journal:  Mol Med       Date:  2009-12-04       Impact factor: 6.354

8.  The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials.

Authors:  J Zheng; P F Shan; W Gu
Journal:  J Endocrinol Invest       Date:  2013-04-12       Impact factor: 4.256

9.  Crosstalk between the AMP-activated kinase and insulin signaling pathways rescues murine blastocyst cells from insulin resistance.

Authors:  Erica Louden; Maggie M Chi; Kelle H Moley
Journal:  Reproduction       Date:  2008-06-24       Impact factor: 3.906

10.  Maternal androgen levels during pregnancy are associated with early-life growth in Geoffroy's marmosets, Callithrix geoffroyi.

Authors:  Adam S Smith; Andrew K Birnie; Jeffrey A French
Journal:  Gen Comp Endocrinol       Date:  2009-10-23       Impact factor: 2.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.